Press Releases

COO Dr. Anthony Maida To Discuss “Industry Innovators Blazing The Trail Towards Successful and Sustained Commercialization” BETHESDA, MD, February 29, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO, Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm on Wednesday, February 29, 2012, in Boston,... Read More

Projections Met or Exceeded For Fourth Consecutive Quarter BETHESDA, MD, February 23, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it now has 30 clinical trial sites open and recruiting across the United States in its ongoing Phase 2 clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company reached this milestone ahead of schedule, as... Read More

Initial Focus On Current 240-Patient GBM Clinical Trial BETHESDA, MD, February 21, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it has entered into an agreement with the American Red Cross to provide blood collection services through which immune cells are obtained to make DCVax®-L treatments for brain cancer patients. The services are focused initially on the Company’s ongoing Phase II clinical trial... Read More

Fifth Annual Emerging Company Forum Being Held In San Francisco In Conjunction With The JP Morgan Annual Healthcare Conference BETHESDA, MD, January 10, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it will be making a presentation today at 10:45 am (PST) in the Windsor Room of the Sir Francis Drake Hotel as part of the fifth annual OneMedForum SF 2012 Conference for emerging biotech companies held over... Read More

Projections Met for Third Consecutive Quarter BETHESDA, MD, January 9, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it successfully met its projection that it would have 25 trial sites open and recruiting by the end of Q4, 2011, in its ongoing clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company likewise met or exceeded the... Read More